Product Description
Quantitative Antibody Blood Tests
Roche Elecsys Anti-SARS-CoV-2-S (Spike) IgG/IgM total antibody test now available.
This blood test enables the determination of both the presence and level of antibodies to the SARS-CoV-2 spike protein, which is the target of many COVID-19 vaccines.
It can can signal whether a person has already been infected and has potentially developed immunity to the virus and plays an important part in characterising a vaccine-induced immune response.
Sensitivity 99.8%, Specificity 98.8%
Sample analysis undertaken by The Doctors Laboratory London (a UKAS accredited laboratory).
Results usually available within 2 days of the sample arriving at the laboratory.
Testing should be undertaken 14 days or more following exposure to or the onset of symptoms.
Further Information:
This blood test enables the determination of both the presence and level of antibodies to the SARS-CoV-2 spike protein, which is the target of many COVID-19 vaccines,. It can can signal whether a person has already been infected and has potentially developed immunity to the virus., and plays an important part in characterising a vaccine-induced immune response.
If an individual has been infected with SARS-CoV-2 they may have detectable antibodies to both the Nucleocapsid (N) and the Receptor Binding Domain (RBD) Spike antigens. Baseline antibody tests for both N and RBD antigens are therefore helpful to identify patients who have been previously infected with SARS-CoV-2.
If an individual has been vaccinated against SARS-CoV-2, with no history of natural infection, the antibodies they develop are to the RBD Spike antigen. As this test targets antibodies against the spike protein, the levels of these antibodies could play a role in establishing vaccine efficacy and vaccine-induced immune response.
